KOSDAQBiotech & Pharma049960

Cell Biotech

₩13,740▲ 1.78%2026-11-18 close
Market Cap
₩129.2B
Turnover
₩53,929,305
Volume
4K
Shares out.
9.4M
PER
10.3×
PBR
0.7×
EPS
₩1,326
Dividend Yield
4.40%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩600 per share · Prices as of the 2026-11-18 close

01

Report overview

Probiotics exporter's profit recovery meets a Q3 2026 net loss

Cell Biotech grew operating profit in 2024 and 2025 on export demand, but swung to a controlling-shareholder net loss in Q3 2026, making the durability of earnings the next checkpoint.

  1. 1

    Overseas sales exceeded 50% of the total in 2025, and the company has kept the top spot in Korean probiotics exports for 13 consecutive years.

  2. 2

    Operating profit rose two years in a row, to KRW 6.8 billion in 2024 and KRW 7.91 billion in 2025, with a 2025 operating margin of 14.9%.

  3. 3

    Q3 2026 turned into a controlling-shareholder net loss of KRW 4.27 billion, and operating profit of KRW 2.01 billion fell 9.4% year on year.

  4. 4

    Nine-month 2026 operating profit of KRW 6.8 billion, up 40.6% year on year, is a provisional figure disclosed on November 6, 2026 before external audit review.

  5. 5

    The microbiome colorectal cancer candidate PP-P8 is in Phase 1 trials, and its safety and efficacy still need to be verified.

02

Business structure

Cell Biotech is a probiotics specialist now in its 31st year, running an integrated production system that covers strain discovery, fermentation, raw material production and finished goods manufacturing on its own technology.

Production is based at five plants in Gimpo, Gyeonggi Province, and products are supplied to 56 countries. Its flagship brand is DUOLAC, which the company differentiates with its dual-coating technology for survival in the intestine.

Overseas sales were reported to have exceeded 50% of the total in 2025, shifting the business focus from domestic health functional foods toward exports.

Reports say the company has held the No. 1 ranking in Korean probiotics exports for 13 consecutive years, and it accounted for KRW 25.9 billion of the KRW 59.6 billion in total Korean probiotics exports in 2023.

A January 2026 report put DUOLAC at No. 1 in Denmark's pharmacy probiotics market with a 46.6% share, although a securities information summary lists the same market at No. 2, so the ranking reads differently depending on the aggregation basis.

The company also runs a business-to-business supply operation providing lactic acid bacteria to European companies. In the domestic market, sales fell in Q1 2025 amid a slump and price competition in health functional foods, while the company said domestic sales grew in Q2 2026 on the DUOLAC advertising campaign.

In pharmaceuticals, the microbiome colorectal cancer candidate PP-P8, which applies genetic engineering, is in Phase 1 and is being advanced while the company reviews relevant standards with the Ministry of Food and Drug Safety.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩15.4B₩2.2B14.4%
2025Q4₩14.6B₩3.1B20.9%
2026Q1₩14.6B₩3.2B21.8%
2026Q2₩15.8B₩1.6B10.4%
2026Q3₩14.8B₩2B13.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩50.5B₩6.1B₩8.3B12.0%7.7%7.2%
2023₩53.8B₩2.2B₩6.3B4.1%5.6%5.1%
2024₩49.9B₩6.8B₩15.1B13.6%12.2%5.0%
2025₩53.1B₩7.9B₩10.1B14.9%7.7%3.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue rose from KRW 50.5 billion in 2022 to KRW 53.8 billion in 2023, a 6.5% increase, then fell to KRW 49.9 billion in 2024, a 7.2% decline, before recovering to KRW 53.1 billion in 2025, a 6.4% increase. Among 2022 to 2025, 2023 was the largest year for revenue and 2024 the smallest.

Operating profit fell from KRW 6.05 billion in 2022 to KRW 2.2 billion in 2023, a 63.7% drop, and then rose to KRW 6.8 billion in 2024, up 209.6%, and KRW 7.91 billion in 2025, up 16.4%, so it grew two years in a row from 2024 to 2025.

The operating margin moved from 12.0% in 2022 to 4.1% in 2023, 13.6% in 2024 and 14.9% in 2025, and 2025 was the largest year for operating profit in the period. The company attributed the 2024 operating profit increase to expanded higher-margin exports and cost efficiency.

Net income that year was also lifted by financial income, including foreign exchange gains, reaching KRW 15.1 billion, up 140.0%.

Controlling-shareholder net income was KRW 8.28 billion in 2022, KRW 6.3 billion in 2023 (down 23.9%), KRW 15.1 billion in 2024 and KRW 10.1 billion in 2025 (down 33.1%), making 2024 the largest year in the period.

Quarterly operating profit reached KRW 3.05 billion in Q4 2025 and KRW 3.19 billion in Q1 2026, the highest levels among the reported quarters.

Operating profit then dropped to KRW 1.64 billion in Q2 2026, down 48.5% from the prior quarter, and recovered to KRW 2.01 billion in Q3 2026, up 22.4% quarter on quarter but down 9.4% year on year. Q3 2026 turned into a controlling-shareholder net loss of KRW 4.27 billion.

Controlling-shareholder net income over the last four quarters, from Q4 2025 to Q3 2026, totaled KRW 9.08 billion.

Provisional figures for January to September 2026 showed revenue of KRW 45.2 billion, up 17.6%, operating profit of KRW 6.8 billion, up 40.6%, and net income of KRW 4.7 billion, down 18.2%, disclosed on November 6, 2026. These are figures before external audit review and may change.

At the end of 2025, total equity was KRW 131.6 billion, controlling-shareholder equity was KRW 131.6 billion, total liabilities were KRW 4.94 billion, and the debt ratio was 3.7%. Operating cash flow was KRW 12.8 billion in 2022, KRW 7.82 billion in 2023, KRW 19.3 billion in 2024 and KRW 11.1 billion in 2025.

05

Industry analysis

Korea's health functional food market slumped in Q1 2025 on temporary weakness and intensifying price competition, and the company said higher-margin export results offset the resulting sales decline.

Over the same period the domestic health functional food industry ran a trade deficit, yet probiotics exports kept the No. 1 position for 13 consecutive years. Total Korean probiotics exports were KRW 59.6 billion in 2023, of which Cell Biotech accounted for KRW 25.9 billion, roughly 43%.

Overseas, reports cited a No. 1 position in Denmark's pharmacy market and an announcement that cumulative exports to Indonesia passed USD 30 million in 2025. The company holds 11 strains on the FDA GRAS list, which it cites as the highest number worldwide and a differentiating factor.

Price competition in the domestic lactic acid bacteria market is a constraint the company itself has pointed to. To respond to tariffs and trade barriers, the company is studying joint ventures and technology transfers in Southeast and Central Asia.

In microbiome drugs, which apply genetic engineering to a new development approach, clinical trials are proceeding while relevant standards are reviewed with the Ministry of Food and Drug Safety.

06

Outlook

In 2025, the 30th anniversary year, the company framed itself as entering full-scale development as a biopharmaceutical company, and it set a long-term vision of becoming a global leader in microbiome drugs by 2055.

Export markets include Denmark, Turkey, Russia and Mexico, with the country count reported as 55 in some materials and 56 in others. Overseas production bases are still at the review stage, and no concrete location or investment plan has been confirmed.

Domestically, the customized probiotics business 'Cellbiome', based on NGS testing, has launched as a new business pillar. In the drug pipeline, the Phase 1 trial of PP-P8 started at Seoul National University Hospital in 2025, and follow-on development direction will become clearer depending on trial results.

The advertising campaign lifted domestic sales in Q2 2026, showing consumer-reach strategy feeding into reported results. The next checkpoint is the annual revenue and operating margin in the 2026 annual report, and Q1 2027 provisional results will be compared against Q1 2026 operating profit of KRW 3.19 billion.

Whether overseas production investment is executed and the outcome of the Phase 1 trial remain the variables that will shape the medium-term growth path.

07

Valuation

PER
10.3×
PBR
0.7×
ROE
7.0%
EPS
₩1,326
BPS
₩19,239
Dividend per share
₩600

Multiple interpretation should be read alongside the direction of earnings changes. Year-end PER was high in 2023, when earnings hit their low point, and lower in 2024 and 2025. Year-end PBR was below 1x in each of 2023, 2024 and 2025 according to aggregated data.

Because total equity far exceeds total liabilities, the multiple against net assets is less distorted by debt. Controlling-shareholder net income in 2024 included financial income, so the earnings-based multiple for that year may read lower than it would on operating earnings alone.

Aggregated data shows the dividend yield well above the average of the KOSDAQ pharmaceutical sector. Operating profit was positive in every year from 2022 to 2025, and profitability has recovered since 2024. The next checkpoint is annual earnings and the dividend decision based on the 2026 annual report.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Export-led overseas growth

Led by the DUOLAC brand, the company has kept the No. 1 ranking in Korean probiotics exports for 13 consecutive years. Overseas sales exceeded 50% of the total in 2025, and a January 2026 report put DUOLAC at No. 1 in Denmark's pharmacy market with a 46.6% share.

Products are sold in 55 to 56 countries depending on the source. The company attributes its earnings improvement to expanded higher-margin exports.

Two years of operating profit growth and margin recovery

Operating profit rose two years in a row, to KRW 6.8 billion in 2024 and KRW 7.91 billion in 2025, while the operating margin climbed from 4.1% in 2023 to 14.9% in 2025. Provisional January to September 2026 operating profit of KRW 6.8 billion was reported, up 40.6% year on year. This figure was disclosed on November 6, 2026 and remains before external audit review.

Financial capacity and drug pipeline

Total equity at the end of 2025 was KRW 131.6 billion against total liabilities of KRW 4.94 billion, a debt ratio of 3.7%. Operating cash flow was KRW 19.3 billion in 2024 and KRW 11.1 billion in 2025. The microbiome colorectal cancer candidate PP-P8 is in Phase 1, and its results could broaden the business structure.

09

Bear factors

Swing to a net loss in Q3 2026

Controlling-shareholder net loss was KRW 4.27 billion in Q3 2026, a swing from profit in the prior quarter, and operating profit of KRW 2.01 billion fell 9.4% year on year. Q2 2026 operating profit of KRW 1.64 billion was down 48.5% from the prior quarter.

Controlling-shareholder net income over the last four quarters totaled KRW 9.08 billion, with large swings between quarters.

Flat revenue and a weak domestic market

Revenue has not returned to the KRW 53.8 billion level of 2023, coming in at KRW 49.9 billion in 2024 and KRW 53.1 billion in 2025. Q3 2026 revenue of KRW 14.8 billion fell 3.3% year on year.

The company said the domestic health functional food market faced a slump and price competition in Q1 2025, and that domestic sales recovered in Q2 2026 alongside the advertising campaign.

Earnings volatility and financial factors

Controlling-shareholder net income fell 33.1% from KRW 15.1 billion in 2024 to KRW 10.1 billion in 2025. The company said 2024 profit was boosted by financial income, including foreign exchange gains, so non-operating factors affect how the results should be read.

Drug development uses genetically modified strains as medicines, so safety and efficacy verification remains an open challenge.

10

Risk factors

Regulatory and clinical risk

Microbiome drugs that apply genetic engineering are advancing in trials while relevant standards are reviewed with the Ministry of Food and Drug Safety, so timelines could shift if standards change. If safety or efficacy cannot be confirmed in Phase 1, the value of the pipeline would change. Follow-on development will depend on trial results.

Trade and currency risk

With overseas sales above 50% of the total, tariffs, trade barriers and currency movements directly affect profitability. The company is studying joint ventures and technology transfers in Southeast and Central Asia in response, but no concrete plan has been confirmed. Financial income, including foreign exchange gains, was part of 2024 profit.

Disclosure and earnings volatility risk

Quarterly operating profit swung from KRW 3.19 billion in Q1 2026 to KRW 1.64 billion in Q2 and KRW 2.01 billion in Q3. Results for January to September 2026 are provisional and may change during external audit review. Confirmed figures will need to be checked in the 2026 annual report.

11

What to watch next

  1. End of March 2027 (annual report filing deadline)

    The 2026 annual report. Checks how full-year revenue and operating margin compare with KRW 53.1 billion and 14.9% in 2025, and whether the January to September 2026 provisional figures hold after audit.

  2. Early 2027 (timing of full-year 2026 provisional results)

    Full-year 2026 provisional results and Q4 2026 figures. Compares Q4 with operating profit of KRW 3.05 billion in Q4 2025 and checks any gap between provisional and annual report figures.

  3. Around May 2027 (Q1 2027 provisional results)

    Q1 2027 results. Checks whether the Q3 2026 swing to a loss persists, against Q1 2026 operating profit of KRW 3.19 billion and controlling-shareholder net income of KRW 5.35 billion.

  4. During 2027 (disclosure timing to be announced)

    Progress of the PP-P8 Phase 1 trial and follow-on development direction. Safety and efficacy results are the key variables for assessing the pipeline.

  5. During 2027 (disclosure timing to be announced)

    Whether joint ventures in Southeast and Central Asia and overseas production bases are confirmed. If so, checks how the scale of capital investment shows up in the financial structure.

12

Overall view

Cell Biotech's revenue has moved around KRW 50 billion since 2022, and operating profit rose two years in a row in 2024 and 2025. Overseas sales above 50% and 13 consecutive years at the top of Korean probiotics exports are cited as strengths.

On the other side, revenue did not regain the KRW 53.8 billion of 2023, and Q3 2026 turned into a controlling-shareholder net loss of KRW 4.27 billion. Provisional January to September 2026 operating profit of KRW 6.8 billion rose year on year, but it is before external audit review.

On financials, total equity of KRW 131.6 billion and a 3.7% debt ratio at the end of 2025 indicate a stable position. The PP-P8 pipeline is in Phase 1, so the timing of any contribution to earnings is uncertain.

With strengths and weaknesses both present, the annual operating margin in the 2026 annual report and Q1 2027 provisional results are the next checkpoints.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. cellbiotech.com
  2. dailypharm.com
  3. venturesquare.net
  4. fnnews.com
  5. etoday.co.kr
  6. comp.fnguide.com
  7. zdnet.co.kr
  8. dailypharm.com
  9. news1.kr
  10. kfdn.co.kr
  11. vegannews.co.kr
  12. m.news.nate.com
  13. edaily.co.kr
  14. edaily.co.kr
  15. edaily.co.kr
  16. m.dailypharm.com
  17. biz.heraldcorp.com
  18. edaily.co.kr

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis